Research Article
Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)
Table 3
The combined phase 1/2 grade ≥3 toxicities separated by attribution.
| | | All grade 3 | All grade 4 | Related grade 3 | Related grade 4 |
| | Blood lymphatic | | Lymphocyte count decreased | 3 (15) | 1 (5) | 2 (10) | 1 (5) | | Platelet count decreased | 1 (5) | 1 (5) | 1 (5) | 1 (5) | | White blood cell decreased | 1 (5) | | | |
| | Gastrointestinal | | Abdominal pain | 1 (5) | | | | | Diarrhea | 3 (15) | | 3 (15) | | | Nausea | 1 (5) | | | | | Obstruction gastric | 1 (5) | | | | | Vomiting | 1 (5) | | | |
| | General | | Edema limbs | 1 (5) | | | | | Fever | 1 (5) | | | | | General disorders and administration site conditions—other, specify | 1 (5) | | | |
| | Hepatobiliary disorders | | Cholecystitis | 2 (10) | | 1 (5) | | | Infections and infestations | | Lung infection | 1 (5) | | | | | Investigations | | | | | | Alanine aminotransferase increased | 1 (5) | | 1 (5) | | | Alkaline phosphatase increased | 3 (15) | | 2 (10) | | | Aspartate aminotransferase increased | | 1 (5) | | 1 (5) |
| | Metabolism and nutrition | | Dehydration | 2 (10) | | 1 (5) | | | Hypercalcemia | 1 (5) | | 1 (5) | | | Hyperglycemia | 1 (5) | | | | | Hypertension | 1 (5) | | 1 (5) | | | Hypoglycemia | 1 (5) | | | | | Hypokalemia | 1 (5) | | 1 (5) | | | Hyponatremia | 1 (5) | | | |
| | Musculoskeletal and connective tissue disorders | | Back pain | 1 (5) | | | | | Neoplasms benign, malignant, and unspecified | | Tumor pain | 1 (5) | | | |
|
|
